Review



vero e6 cells bcrc number: 60476  (BioResource International Inc)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    BioResource International Inc vero e6 cells bcrc number: 60476
    Combined treatments of ciclesonide and tylophorine-based dbq33b synergistically inhibited coronaviral replication. ( A ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited HCoV-OC43 infection/replication in human fetal lung fibroblast MRC-5 cells assayed by IFA. ( B ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited SARS-CoV-2 infection/replication in <t>Vero</t> <t>E6</t> cells assayed by IFA. ( C ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically reduced infectious SARS-CoV-2 viral loads as determined by plaque formation assays. IFAs were performed with antibody against viral N protein (green) in HCoV-OC43-infected MRC-5 (0.05 MOI) at 30 h.p.i. treated with vehicle (0.5% DMSO) or compounds as indicated. Nuclei (blue) were counterstained with Hoechst dye and used to determine the relative cell viability by using the number of nuclei in vehicle control as 100%. The Methods used for IFA and plaque assays for SARS-CoV-2 infectivity in Vero E6 cells were performed and analyzed as described . The effects of single treatments within indicated concentrations were shown as AVE ± S.D. from three independent experiments ( Aa , Ba , C ). IFA or plaque formation images ( Ab , Bb , C ) shown are representative of three independent experiments. (* p < 0.05, ** p < 0.01, *** p < 0.001). Shown synergy scores are AVE ± S.D. from three independent experiments ( Ac , Bc ) analyzed via the online SynergyFinder ( https://synergyfinder.fimm.fi/ , accessed on 23 March 2021).
    Vero E6 Cells Bcrc Number: 60476, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vero e6 cells bcrc number: 60476/product/BioResource International Inc
    Average 90 stars, based on 1 article reviews
    vero e6 cells bcrc number: 60476 - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b"

    Article Title: The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b

    Journal: Pharmaceutics

    doi: 10.3390/pharmaceutics14071511

    Combined treatments of ciclesonide and tylophorine-based dbq33b synergistically inhibited coronaviral replication. ( A ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited HCoV-OC43 infection/replication in human fetal lung fibroblast MRC-5 cells assayed by IFA. ( B ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited SARS-CoV-2 infection/replication in Vero E6 cells assayed by IFA. ( C ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically reduced infectious SARS-CoV-2 viral loads as determined by plaque formation assays. IFAs were performed with antibody against viral N protein (green) in HCoV-OC43-infected MRC-5 (0.05 MOI) at 30 h.p.i. treated with vehicle (0.5% DMSO) or compounds as indicated. Nuclei (blue) were counterstained with Hoechst dye and used to determine the relative cell viability by using the number of nuclei in vehicle control as 100%. The Methods used for IFA and plaque assays for SARS-CoV-2 infectivity in Vero E6 cells were performed and analyzed as described . The effects of single treatments within indicated concentrations were shown as AVE ± S.D. from three independent experiments ( Aa , Ba , C ). IFA or plaque formation images ( Ab , Bb , C ) shown are representative of three independent experiments. (* p < 0.05, ** p < 0.01, *** p < 0.001). Shown synergy scores are AVE ± S.D. from three independent experiments ( Ac , Bc ) analyzed via the online SynergyFinder ( https://synergyfinder.fimm.fi/ , accessed on 23 March 2021).
    Figure Legend Snippet: Combined treatments of ciclesonide and tylophorine-based dbq33b synergistically inhibited coronaviral replication. ( A ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited HCoV-OC43 infection/replication in human fetal lung fibroblast MRC-5 cells assayed by IFA. ( B ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited SARS-CoV-2 infection/replication in Vero E6 cells assayed by IFA. ( C ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically reduced infectious SARS-CoV-2 viral loads as determined by plaque formation assays. IFAs were performed with antibody against viral N protein (green) in HCoV-OC43-infected MRC-5 (0.05 MOI) at 30 h.p.i. treated with vehicle (0.5% DMSO) or compounds as indicated. Nuclei (blue) were counterstained with Hoechst dye and used to determine the relative cell viability by using the number of nuclei in vehicle control as 100%. The Methods used for IFA and plaque assays for SARS-CoV-2 infectivity in Vero E6 cells were performed and analyzed as described . The effects of single treatments within indicated concentrations were shown as AVE ± S.D. from three independent experiments ( Aa , Ba , C ). IFA or plaque formation images ( Ab , Bb , C ) shown are representative of three independent experiments. (* p < 0.05, ** p < 0.01, *** p < 0.001). Shown synergy scores are AVE ± S.D. from three independent experiments ( Ac , Bc ) analyzed via the online SynergyFinder ( https://synergyfinder.fimm.fi/ , accessed on 23 March 2021).

    Techniques Used: Infection, Control

    The synergistic inhibition of coronaviral replication in HCoV-OC43-infected MRC-5 cells and SARS-CoV-2-infected Vero E6 cells after treatment with the combination of ciclesonide and dbq33b.
    Figure Legend Snippet: The synergistic inhibition of coronaviral replication in HCoV-OC43-infected MRC-5 cells and SARS-CoV-2-infected Vero E6 cells after treatment with the combination of ciclesonide and dbq33b.

    Techniques Used: Inhibition



    Similar Products

    vero e6 cells bcrc number: 60476  (BioResource International Inc)
    90
    BioResource International Inc vero e6 cells bcrc number: 60476
    Combined treatments of ciclesonide and tylophorine-based dbq33b synergistically inhibited coronaviral replication. ( A ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited HCoV-OC43 infection/replication in human fetal lung fibroblast MRC-5 cells assayed by IFA. ( B ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited SARS-CoV-2 infection/replication in <t>Vero</t> <t>E6</t> cells assayed by IFA. ( C ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically reduced infectious SARS-CoV-2 viral loads as determined by plaque formation assays. IFAs were performed with antibody against viral N protein (green) in HCoV-OC43-infected MRC-5 (0.05 MOI) at 30 h.p.i. treated with vehicle (0.5% DMSO) or compounds as indicated. Nuclei (blue) were counterstained with Hoechst dye and used to determine the relative cell viability by using the number of nuclei in vehicle control as 100%. The Methods used for IFA and plaque assays for SARS-CoV-2 infectivity in Vero E6 cells were performed and analyzed as described . The effects of single treatments within indicated concentrations were shown as AVE ± S.D. from three independent experiments ( Aa , Ba , C ). IFA or plaque formation images ( Ab , Bb , C ) shown are representative of three independent experiments. (* p < 0.05, ** p < 0.01, *** p < 0.001). Shown synergy scores are AVE ± S.D. from three independent experiments ( Ac , Bc ) analyzed via the online SynergyFinder ( https://synergyfinder.fimm.fi/ , accessed on 23 March 2021).
    Vero E6 Cells Bcrc Number: 60476, supplied by BioResource International Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/vero e6 cells bcrc number: 60476/product/BioResource International Inc
    Average 90 stars, based on 1 article reviews
    vero e6 cells bcrc number: 60476 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Combined treatments of ciclesonide and tylophorine-based dbq33b synergistically inhibited coronaviral replication. ( A ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited HCoV-OC43 infection/replication in human fetal lung fibroblast MRC-5 cells assayed by IFA. ( B ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited SARS-CoV-2 infection/replication in Vero E6 cells assayed by IFA. ( C ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically reduced infectious SARS-CoV-2 viral loads as determined by plaque formation assays. IFAs were performed with antibody against viral N protein (green) in HCoV-OC43-infected MRC-5 (0.05 MOI) at 30 h.p.i. treated with vehicle (0.5% DMSO) or compounds as indicated. Nuclei (blue) were counterstained with Hoechst dye and used to determine the relative cell viability by using the number of nuclei in vehicle control as 100%. The Methods used for IFA and plaque assays for SARS-CoV-2 infectivity in Vero E6 cells were performed and analyzed as described . The effects of single treatments within indicated concentrations were shown as AVE ± S.D. from three independent experiments ( Aa , Ba , C ). IFA or plaque formation images ( Ab , Bb , C ) shown are representative of three independent experiments. (* p < 0.05, ** p < 0.01, *** p < 0.001). Shown synergy scores are AVE ± S.D. from three independent experiments ( Ac , Bc ) analyzed via the online SynergyFinder ( https://synergyfinder.fimm.fi/ , accessed on 23 March 2021).

    Journal: Pharmaceutics

    Article Title: The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b

    doi: 10.3390/pharmaceutics14071511

    Figure Lengend Snippet: Combined treatments of ciclesonide and tylophorine-based dbq33b synergistically inhibited coronaviral replication. ( A ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited HCoV-OC43 infection/replication in human fetal lung fibroblast MRC-5 cells assayed by IFA. ( B ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically inhibited SARS-CoV-2 infection/replication in Vero E6 cells assayed by IFA. ( C ) Combined treatment of ciclesonide and tylophorine-based dbq33b synergistically reduced infectious SARS-CoV-2 viral loads as determined by plaque formation assays. IFAs were performed with antibody against viral N protein (green) in HCoV-OC43-infected MRC-5 (0.05 MOI) at 30 h.p.i. treated with vehicle (0.5% DMSO) or compounds as indicated. Nuclei (blue) were counterstained with Hoechst dye and used to determine the relative cell viability by using the number of nuclei in vehicle control as 100%. The Methods used for IFA and plaque assays for SARS-CoV-2 infectivity in Vero E6 cells were performed and analyzed as described . The effects of single treatments within indicated concentrations were shown as AVE ± S.D. from three independent experiments ( Aa , Ba , C ). IFA or plaque formation images ( Ab , Bb , C ) shown are representative of three independent experiments. (* p < 0.05, ** p < 0.01, *** p < 0.001). Shown synergy scores are AVE ± S.D. from three independent experiments ( Ac , Bc ) analyzed via the online SynergyFinder ( https://synergyfinder.fimm.fi/ , accessed on 23 March 2021).

    Article Snippet: HCT-8 colon adenocarcinoma cells (ATCC ® CCL-244TM), MRC-5 lung fibroblasts cells (ATCC ® CCL-171TM), and the OC43 strain of human coronavirus (HCoV-OC43, ATCC ® VR1558TM) were purchased from American Type Culture Collection (ATCC), USA, and Vero E6 cells (BCRC number: 60476; derived from ATCC CRL-1586) from Bioresource Collection and Research Center (BCRC), Hsinchu, Taiwan.

    Techniques: Infection, Control

    The synergistic inhibition of coronaviral replication in HCoV-OC43-infected MRC-5 cells and SARS-CoV-2-infected Vero E6 cells after treatment with the combination of ciclesonide and dbq33b.

    Journal: Pharmaceutics

    Article Title: The Synergistic Inhibition of Coronavirus Replication and Induced Cytokine Production by Ciclesonide and the Tylophorine-Based Compound Dbq33b

    doi: 10.3390/pharmaceutics14071511

    Figure Lengend Snippet: The synergistic inhibition of coronaviral replication in HCoV-OC43-infected MRC-5 cells and SARS-CoV-2-infected Vero E6 cells after treatment with the combination of ciclesonide and dbq33b.

    Article Snippet: HCT-8 colon adenocarcinoma cells (ATCC ® CCL-244TM), MRC-5 lung fibroblasts cells (ATCC ® CCL-171TM), and the OC43 strain of human coronavirus (HCoV-OC43, ATCC ® VR1558TM) were purchased from American Type Culture Collection (ATCC), USA, and Vero E6 cells (BCRC number: 60476; derived from ATCC CRL-1586) from Bioresource Collection and Research Center (BCRC), Hsinchu, Taiwan.

    Techniques: Inhibition